Business Wire

VACCINES-EUROPE

21.1.2020 07:37:09 CET | Business Wire | Press release

Share
Call to Boost Collaborative Efforts to Save Lives by Reaching Seasonal Influenza Vaccination Targets Across the EU (Vaccines Europe)

At an event held in the European Parliament today, policymakers noted the lack of progress made by EU Member States towards the EU’s 75% target for seasonal influenza vaccination coverage rates among older-age and at-risk groupsi , first adopted in the EU Council Recommendation on seasonal influenza vaccination in 2009.ii

Speakers from the European Commission, European Parliament, European Centre for Disease Prevention and Control (ECDC) and World Health Organisation (WHO) all agreed on the need to seize the opportunity presented by the 10-year milestone of the 2009 Recommendation to renew efforts to boost coverage rates and address the major public health challenges associated with seasonal influenza.

Building on a new study on public perceptions of seasonal influenza disease and vaccination in four EU countriesiii and leveraging some national best practices, panellists stressed the need for all influenza stakeholders to gather in simultaneously addressing influenza vaccine confidence, convenience and complacency issues.

Potential solutions were discussed and identified, which would help addressing specific challenges and make progress towards the ten-year-old 75% seasonal influenza vaccination target, such as:

  • Voluntary exchange of best practices between EU countries on how to increase seasonal influenza vaccination rates. This could be done as part of the EU State of Health initiative cycle.iv Following the publication of Country Health Profiles 2019, the European Commission could establish voluntary exchanges between EU countries, in particular focusing on seasonal influenza vaccination policies and programmesv .
  • EU guidance on data collection for seasonal influenza vaccine coverage rates. This should cover what should be collected, when and how . Currently, data is collected differently and at different times in various EU Member States, which creates an uneven and patchy picture across the EU. An EU Guidance on data collection will allow to monitor whether the EU’s 75% target has been met in all at risk or targeted groups as well as propose appropriate measures to achieve it.
  • Measures to allow all competent healthcare professionals to provide vaccination in convenient locations. For example, by allowing vaccine administration in locations such as workplaces, community pharmacies and schools. Evidence shows that in countries where pharmacists can administer vaccines, the number of people vaccinated increases.vi The EU has a role to play in sharing best practices and providing guidance, and EU Member States will need to introduce appropriate legislations and policies to implement these practices.
  • Further work by EU Member States, as well as the EU and WHO, needs to improve knowledge/education of and confidence in, vaccines among both citizens and healthcare professionals. In some countries, as many as 36.4% of GPs do not believe that the seasonal influenza vaccination is important, and elsewhere the percentage of the general public who believe that it is important is as low as 40.4%. Countries such as Spain and Portugal showcase best practices, with public confidence rates of almost 80%.vii
  • All influenza actors should join forces in, for example, a multi-stakeholder coalitionviii , and launch an European Influenza Awareness Day , that would help to boost influenza vaccination confidence.

MEP Dolors Montserrat (EPP, ES), co-host of the event and former Spanish Health Minister, said that “to progress towards a broader vaccination coverage, especially for people with chronic diseases, we need to:

  1. Raise awareness among healthcare professionals, and policy makers on the problem to build trust in institutions and providers of vaccines;
  2. Empower patients to be correctly informed and participate in the decision making process on the adequate and most cost-effective therapies for their health;
  3. Fight the fake news and the misinformation campaigns through promoting sources of reliable information about vaccination, exposure to positive media messages.”

“The EU has given vaccination a lot of political attention recently – not least through the 2018 Council Recommendation on Strengthened Cooperation Against Vaccine-Preventable Diseases, the EU Joint Action on Vaccination, and the 2019 Global Vaccination Summit. But dwindling seasonal influenza vaccination coverage rates show that much more needs to be done – both at EU and national level” said Magdalena R. de Azero, Executive Director of Vaccines Europe, which organised the event. Ms de Azero concluded: “This event underlines the need for institutions, governments, healthcare professionals and industry to work together to address this challenge.”

Notes

Seasonal influenza poses a significant but often under-recognised challenge to EU health systems. Compared to other infectious diseases, it has the highest impact in terms of mortality and incidence and is estimated to cause up to 70,000 deaths in the EU each year, particularly among older age groups.ixx Its impact is particularly acute among the elderly and other at-risk groups.

Latest EU data (2017, published in 2019) shows that no EU Member State has reached the 75% target for coverage rates. In fact, many countries have seen rates decline, some going as low as single digits (Latvia 6.9%, Estonia 4.8%). The best-in-class EU country, the UK, has seen rates consistently around 70% in recent years (currently 72.6%).xi

About Vaccines Europe

Formed in 1991, Vaccines Europe is a specialised group of the European Federation of Pharmaceutical Industries and Associations (EFPIA) that represents major innovative research-based vaccine companies as well as small and medium-sized enterprises operating in Europe which account for a large share of human vaccines used worldwide.

i As defined by ECDC. https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/risk-groups
ii https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:348:0071:0072:EN:PDF
iii Full study to be published in the near future. Presented by Professor Frederic Bouder of the University of Stavanger.
iv https://ec.europa.eu/health/state/summary_en
v https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_services_en.pdf .
vi https://www.vaccinestoday.eu/stories/does-pharmacy-vaccination-increase-overall-uptake/
vii https://ec.europa.eu/health/sites/health/files/vaccination/docs/2018_vaccine_confidence_en.pdf
viii For example: https://www.immunize.org/
ix https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2018.23.16.17-00454
x https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet
xi https://ec.europa.eu/eurostat/web/products-eurostat-news/product/-/asset_publisher/VWJkHuaYvLIN/content/DDN-20191209-2

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lone Star Funds Completes Acquisition of Alliance Ground International26.3.2026 13:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has completed the acquisition of Alliance Ground International (“AGI”), a leading North American airport services provider. “We are excited to partner with the AGI management team to drive the business forward,” said Donald Quintin, Chief Executive Officer of Lone Star. “The company has a superior service offering and a track record of success across its integrated operations. We see opportunities to continue to invest in the business and its people to continue to grow its capabilities and ensure it remains best-in-class in delivering for the aviation industry.” “Today marks an important next step for AGI as we move forward in partnership with Lone Star,” said Jared Azcuy, Chief Executive Officer of AGI. “Our commitment to safety, reliability, and operational service excellence remains unchanged. This partnership strengthens our ability to deliver for our airline partners and reinforces that the

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging26.3.2026 13:30:00 CET | Press release

The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship between target engagement and clinical improvement in psoriasis and atopic dermatitis RLS-1496 is a first-in-class disease-modifying mechanism targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases of aging A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States, with completion expected later this year Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, to moderate panel on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology (AAD) annual meeting on Thursday, March 26, at 1:05 pm MT in Denver Oral presentation of data accepted at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago Rubedo L

GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe26.3.2026 13:30:00 CET | Press release

COMPASS is one of the largest public‑private partnerships under the European Union’s (EU) Innovative Health Initiative (IHI). The consortium aims to advance early detection and prediction of cardiotoxicity in cancer patients and cancer survivors. The initiative will leverage AI, advanced imaging, biomarkers, and integrated care pathways. GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the IHI. Cardiovascular diseases are rising sharply among cancer patients and survivors, driven both by the increasing prevalence of pre‑existing cardiovascular conditions at diagnosis and by

M1X Global Announces Public Launch and Oversubscribed $3 Million Angel Round to Scale On-Chain Sovereign Finance26.3.2026 13:13:00 CET | Press release

M1X Global, a sovereign financial infrastructure and technology company, today announced its public launch alongside the close of an oversubscribed $3 million angel round. The funding, spanning strategic investments and grants, will support platform development and accelerate regulated institutional adoption of USDM1, the first USD-denominated, treasury collateralized sovereign debt instrument issued natively by a sovereign on public blockchain infrastructure. The $3 million in funding drew participation from leading figures across global capital markets and digital asset infrastructure, including Balaji Srinivasan, former CTO of Coinbase; Tama Churchouse, CEO of Cumberland Labs; Richard Gorelick, former Head of Market Structure at DRW; and Dan Robichaud, former CIO at Intel. Institutional participation from FJ Labs and grant funding from Stellar Development Foundation reflect strong alignment between private capital and mission-driven partners advancing blockchain-based market develop

500 Global Taps Former IFC CIO As Firm Expands Global Investment Platform26.3.2026 13:00:00 CET | Press release

Atul Mehta brings three decades of global investment leadership to board as 500 Global scales platforms aligning venture capital with national innovation and economic growth agendas. 500 Global today announced the appointment of Atul Mehta to its Board of Directors, marking an important step in the firm’s continued evolution as a global venture platform and institutional asset manager. Mehta brings more than three decades of global investment and institutional leadership experience at a time when 500 Global has observed governments, multilateral institutions, and long-term capital providers rethinking how technology-led growth is financed and scaled. He has held senior roles across private capital and development finance, including at the International Finance Corporation (IFC), where he managed multi-billion-dollar portfolios spanning technology, venture funds, infrastructure, agribusiness, healthcare, education, and financial services across emerging markets. Over his career, he has

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye